BCYC Stock Overview
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics.
Bicycle Therapeutics Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$23.45|
|52 Week High||US$62.08|
|52 Week Low||US$12.08|
|1 Month Change||-8.90%|
|3 Month Change||26.62%|
|1 Year Change||-47.78%|
|3 Year Change||134.62%|
|5 Year Change||n/a|
|Change since IPO||95.42%|
Recent News & Updates
Bicycle Therapeutics initiated Outperform at Cowen citing drug platform
Cowen launched its coverage on oncology-focused biotech Bicycle Therapeutics (NASDAQ:BCYC) on Wednesday, arguing that the company’s therapeutic platform of bicycle toxin conjugates (BTC) can outshine another cancer drug class called antibody-drug conjugates (ADC). The smaller size, better cancer specificity, and lower systemic effects compared to ADCs make BTCs the most uniquely suitable candidates to treat tumors such as urothelial cancer and ovarian cancer, the analysts led by Tara Bancroft argue. During Q3 2022, BCYC plans to share results from the dose escalation portion of a Phase I/II study for its BTC candidate BT5528, which analysts said could validate its peak sales potential and the BTC platform. BT5528, a BTC designed to target EphA2-expressing tumors, is expected to add ~$650M peak sales by 2035, Bancroft and the team project. In addition, Cowen estimates that the company’s second-generation BTC BT8009 that targets Nectin-4 tumors could achieve ~$1B peak sales by 2035. In April, BCYC shares whipsawed after the company announced Phase 1/2 data for BT8009 at the 2022 American Association for Cancer Research (AACR) Annual Meeting.
Bicycle to get $10M as Genentech uses option for new program under cancer drug collaboration
Bicycle Therapeutics (NASDAQ:BCYC) will get $10M from Genentech as the Roche (OTCQX:RHHBY) (OTCQX:RHHBF) unit exercised its second option to begin a new program under a collaboration to discover, develop and sell novel immuno-oncology therapies. The two companies entered a collaboration in February 2020 for the discovery and pre-clinical development of novel Bicycle-based immunotherapies for multiple targets. Genentech was granted the right to add two additional programs, one of which was exercised by the Roche unit in October 2021 triggering a $10M payment while the second has been exercised now. Bicycle noted that none of the compounds in its wholly owned cancer pipeline, including its immuno-oncology candidates, are included in the collaboration.
|BCYC||US Biotechs||US Market|
Return vs Industry: BCYC underperformed the US Biotechs industry which returned -22.7% over the past year.
Return vs Market: BCYC underperformed the US Market which returned -20% over the past year.
|BCYC Average Weekly Movement||9.0%|
|Biotechs Industry Average Movement||11.1%|
|Market Average Movement||6.9%|
|10% most volatile stocks in US Market||15.5%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: BCYC is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: BCYC's weekly volatility (9%) has been stable over the past year.
About the Company
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company’s oncology product candidates also comprise BT5528, a BTC that is in a Phase I/II clinical trial targeting EphA2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4.
Bicycle Therapeutics Fundamentals Summary
|BCYC fundamental statistics|
Is BCYC overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|BCYC income statement (TTM)|
|Cost of Revenue||US$57.60m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-2.94|
|Net Profit Margin||-533.03%|
How did BCYC perform over the long term?See historical performance and comparison
Is BCYC undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 0/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for BCYC?
Other financial metrics that can be useful for relative valuation.
|What is BCYC's n/a Ratio?|
Price to Sales Ratio vs Peers
How does BCYC's PS Ratio compare to its peers?
|BCYC PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
SGMO Sangamo Therapeutics
EDIT Editas Medicine
CHRS Coherus BioSciences
BCYC Bicycle Therapeutics
Price-To-Sales vs Peers: BCYC is expensive based on its Price-To-Sales Ratio (42.6x) compared to the peer average (12.6x).
Price to Earnings Ratio vs Industry
How does BCYC's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Sales vs Industry: BCYC is expensive based on its Price-To-Sales Ratio (42.6x) compared to the US Biotechs industry average (13.1x)
Price to Sales Ratio vs Fair Ratio
What is BCYC's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||42.6x|
|Fair PS Ratio||0.8x|
Price-To-Sales vs Fair Ratio: BCYC is expensive based on its Price-To-Sales Ratio (42.6x) compared to the estimated Fair Price-To-Sales Ratio (0.8x).
Share Price vs Fair Value
What is the Fair Price of BCYC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate BCYC's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate BCYC's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
How is Bicycle Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 14 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BCYC is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: BCYC is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: BCYC is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: BCYC's revenue (60.5% per year) is forecast to grow faster than the US market (7.6% per year).
High Growth Revenue: BCYC's revenue (60.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: BCYC is forecast to be unprofitable in 3 years.
Discover growth companies
How has Bicycle Therapeutics performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BCYC is currently unprofitable.
Growing Profit Margin: BCYC is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: BCYC is unprofitable, and losses have increased over the past 5 years at a rate of 35% per year.
Accelerating Growth: Unable to compare BCYC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BCYC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (29.2%).
Return on Equity
High ROE: BCYC has a negative Return on Equity (-27.97%), as it is currently unprofitable.
Discover strong past performing companies
How is Bicycle Therapeutics's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: BCYC's short term assets ($408.5M) exceed its short term liabilities ($41.3M).
Long Term Liabilities: BCYC's short term assets ($408.5M) exceed its long term liabilities ($92.7M).
Debt to Equity History and Analysis
Debt Level: BCYC has more cash than its total debt.
Reducing Debt: Insufficient data to determine if BCYC's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: BCYC has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: BCYC has sufficient cash runway for 2.4 years if free cash flow continues to reduce at historical rates of 20.7% each year.
Discover healthy companies
What is Bicycle Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
|Bicycle Therapeutics Dividend Yield vs Market|
|Company (Bicycle Therapeutics)||n/a|
|Market Bottom 25% (US)||1.6%|
|Market Top 25% (US)||4.5%|
|Industry Average (Biotechs)||2.7%|
|Analyst forecast in 3 Years (Bicycle Therapeutics)||n/a|
Notable Dividend: Unable to evaluate BCYC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate BCYC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if BCYC's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BCYC's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as BCYC has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Kevin Lee (53 yo)
Dr. Kevin Lee, M.B.A., Ph D., has been Chief Executive Officer of Bicycle Therapeutics plc since September 2015. Dr. Lee joined Bicycle Therapeutics from Pfizer where he served as Senior Vice President and...
CEO Compensation Analysis
|Kevin Lee's Compensation vs Bicycle Therapeutics Earnings|
|Date||Total Comp.||Salary||Company Earnings|
|Jun 30 2022||n/a||n/a|
|Mar 31 2022||n/a||n/a|
|Dec 31 2021||US$4m||US$677k|
|Sep 30 2021||n/a||n/a|
|Jun 30 2021||n/a||n/a|
|Mar 31 2021||n/a||n/a|
|Dec 31 2020||US$3m||US$592k|
|Sep 30 2020||n/a||n/a|
|Jun 30 2020||n/a||n/a|
|Mar 31 2020||n/a||n/a|
|Dec 31 2019||US$4m||US$517k|
|Sep 30 2019||n/a||n/a|
|Jun 30 2019||n/a||n/a|
|Mar 31 2019||n/a||n/a|
|Dec 31 2018||US$818k||US$386k|
Compensation vs Market: Kevin's total compensation ($USD4.47M) is about average for companies of similar size in the US market ($USD4.09M).
Compensation vs Earnings: Kevin's compensation has increased whilst the company is unprofitable.
Experienced Management: BCYC's management team is considered experienced (3.9 years average tenure).
Experienced Board: BCYC's board of directors are considered experienced (3.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
|Owner Type||Number of Shares||Ownership Percentage|
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 16.3%.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
Bicycle Therapeutics plc's employee growth, exchange listings and data sources
- Name: Bicycle Therapeutics plc
- Ticker: BCYC
- Exchange: NasdaqGS
- Founded: 2009
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$695.905m
- Shares outstanding: 29.68m
- Website: https://www.bicycletherapeutics.com
Number of Employees
- Bicycle Therapeutics plc
- Babraham Research Campus
- Building 900
- CB22 3AT
- United Kingdom
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|BCYC||NasdaqGS (Nasdaq Global Select)||Yes||SPON ADS EACH REP 1 ORD SHS||US||USD||May 2019|
|50BA||DB (Deutsche Boerse AG)||Yes||SPON ADS EACH REP 1 ORD SHS||DE||EUR||May 2019|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/10/04 00:00|
|End of Day Share Price||2022/10/04 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.